Ortin Global Limited approved a major restructuring of its board of directors during a meeting held on September 7, 2026. The changes include the appointment of a new Managing Director and the resignation of a Whole-time Director.

The board also approved the notice for the company’s 39th Annual General Meeting (AGM), scheduled for September 30, 2026.

Board Restructuring Details

The most significant change involves the leadership transition at the executive level. Mr. Prakash Prashanth Sawant has been appointed as Managing Director for a three-year term, effective from September 7, 2026, until September 6, 2029. This appointment is subject to shareholder approval at the upcoming AGM.

Concurrently, Mr. Murali Krishna Murthy Sanka will step down from his role as Managing Director to become a Non-Executive Director, effective immediately. His new designation is also subject to member approval.

The board accepted the resignation of Mrs. Prakruti Prashant Sawant from the post of Whole-time Director, effective September 7, 2026. The filing cites professional commitments as the reason for her departure.

New Appointments

Mr. Parveen Satija was appointed as an Additional Director and Whole-time Director for a two-year term, running from September 7, 2026, to September 6, 2028. This appointment requires ratification by shareholders.

Mr. Satija brings experience in corporate leadership, governance, and statutory compliance. He currently holds 1,00,526 equity shares in the company. The board affirmed that he is not debarred from holding office under any SEBI order.

AGM Schedule

The company’s 39th Annual General Meeting for FY26 will be conducted via video conference or other audio-visual means (OAVM). The meeting is scheduled for Wednesday, September 30, 2026, at 5:00 pm.

The agenda includes the approval of the director designation changes outlined above, alongside the standard consideration of the Directors’ Report for the financial year ending March 31, 2026.

What the Numbers Show

The shift in leadership marks a transition from long-term founding management to specialized executive oversight. Mr. Sanka, who started the pharma distribution business in 1978, retains influence as a Non-Executive Director while holding 17,844 equity shares. In contrast, the incoming Managing Director, Mr. Sawant, brings external expertise from JP Morgan Chase and technical analysis, signaling a potential focus on strategic financial management and market dynamics rather than purely operational legacy.

Ortin Global Limited has clarified to the National Stock Exchange of India Limited that the requirement for reporting segment details is not applicable to the company. The firm stated it operates in only one segment, Drugs and Medicines. This disclosure was made in response to an exchange query regarding the financial results for the quarter and year ended March 31, 2026.

The National Stock Exchange of India Limited had sought clarification on June 27, 2026, specifically regarding the absence of segment details in the filing. In its reply dated July 9, 2026, the company explained that since it does not have multiple reportable business segments, the specific disclosure requirement does not apply to its financial reporting structure.

The communication was signed by S. Murali Krishna Murthy, Managing Director of Ortin Global Limited. The company confirmed that its entire operations fall under the Drugs and Medicines category, thereby exempting it from the detailed segment reporting standards applicable to multi-business entities.